Q2 2023 Dynavax Technologies Corporation Earnings Call

Speaker 1: of a immunogenicity endpoint that we can use to bridge back to in larger studies. So this is an initial challenge study. It's likely and expected that we would have to do larger challenge studies in addition to this one as part of the longer term development plan. It's important to also recognize this isn't this is a new study design that hasn't really been done before with a vaccine for pertussis. So we're working with an investigator now to help support his development of a challenge model where we can use a vaccine and allow disease to progress to identify and test efficacy from humans. And so this pilot study is important on a number of fronts, one for our product and also to establish the model. That makes sense. Thanks so much. Absolutely. Thank you for the question. Thank you.

Speaker 1: And we have no further questions at this time. I would like to hand the conference back over to Mr. Ryan Spencer, Chief Executive Officer, for closing remarks. You may begin. Thank you, Operator. And thank you all for joining us today. We appreciate your interest in DynaVax. We are very excited about our continued progress and the strength of our position, which we believe allows us to focus on executing our long-term objectives to drive value through advancement of meaningful products.

Speaker 2: to help protect the world from infectious diseases. We look forward to updating you on our progress. Operator, you may end the call. Thank you. Ladies and gentlemen, thank you for joining us today. This concludes today's conference call. You may now disconnect. Everyone have a wonderful day.